Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases. The company commercializes three approved medicines: Livmarli for cholestatic pruritus in Alagille syndrome and progressive familial intrahepatic cholestasis, Cholbam for bile acid synthesis disorders and peroxisomal disorders, and Ctexli for cerebrotendinous xanthomatosis. In addition, Mirum advances a pipeline of product candidates including volixibat for primary sclerosing cholangitis and primary biliary cholangitis, brelovitug for chronic hepatitis D virus infection, and MRM-3379 for fragile X syndrome. The firm focuses its efforts on orphan indications where unmet medical need is high.

Mirum generates revenue primarily from the sale of its approved medicines Livmarli, Cholbam, and Ctexli in the United States, Canada, and select European countries through a specialized commercial team. The company also earns revenue from licensing and distribution agreements with rare disease partners that enable commercialization of its products in additional territories. Furthermore, milestone payments and royalties from collaborative agreements contribute to its overall income.

Within the rare disease biopharmaceutical sector, Mirum holds a competitive position through its approved therapies for niche liver conditions and its pipeline targeting underserved indications. Key competitors include GlaxoSmithKline and Ipsen which develop IBAT inhibitors for similar cholestatic diseases, as well as companies pursuing gene therapy solutions for progressive familial intrahepatic cholestasis. For its hepatitis D candidate, Mirum faces competition from Gilead Sciences’ bulevirtide and other investigational agents. In the fragile X syndrome space, rivals such as Shionogi and Harmony Biosciences are advancing PDE4D inhibitors. Mirum’s advantages stem from its orphan drug exclusivities, specialized sales force focused on rare disease specialists, and a broad intellectual property portfolio that protects its product candidates.

The company serves patients with rare liver and genetic diseases, their treating physicians, and specialized healthcare providers. Its products are distributed through specialty pharmacies, third party logistics providers, authorized distributors, and licensed partners in various jurisdictions. In certain markets, government agencies also place periodic orders for its medicines.